Similar articles

• High QT dispersion in tacrolimus-treated kidney transplant recipients.

  Gerhardt U, Suwelack B, Pawolka A, Hohage H. Gerhardt U, et al. Transplant Proc. 2001 May;33(3):2148-50. doi: 10.1016/s0041-1345(01)01924-8. Transplant Proc. 2001. PMID: 11377482 No abstract available.
• Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection.

  Shoker A, George D, Yang H, Baltzan M. Shoker A, et al. Transplantation. 2000 Aug 15;70(3):497-505. doi: 10.1097/00007890-200008150-00018. Transplantation. 2000. PMID: 10949194
• Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.

  Yussim A, Shaharabani E, Mor E, Lustig S, Bar-Nathan N, Shmueli D, Sobolev V, Dorfman B, Or H, Shapira Z. Yussim A, et al. Transplant Proc. 1996 Dec;28(6):3178-9. Transplant Proc. 1996. PMID: 8962233 No abstract available.
• Tacrolimus (FK 506) in kidney transplantation.

  Vanrenterghem Y. Vanrenterghem Y. Transplant Proc. 1998 Aug;30(5):2171-3. doi: 10.1016/s0041-1345(98)00578-8. Transplant Proc. 1998. PMID: 9723431 Review. No abstract available.
• Cyclosporine: the principal immunosuppressant for renal transplantation.

  Keown PA, Primmett DR. Keown PA, et al. Transplant Proc. 1998 Aug;30(5):1712-5. doi: 10.1016/s0041-1345(98)00401-1. Transplant Proc. 1998. PMID: 9723252 Review. No abstract available.